BRAIN Biotech

Отрасль

Косметика, Корма, Промышленная химия

Темы

Ферменты и биокатализ, Корма и кормовые добавки, Гиалуроновая кислота, коллаген и активные вещества для косметики

Роль

Производитель — “…signed to move products and processes forward with innovative biosolutions. They position themselves as a part…”

Почему это биоэкономика

BRAIN Biotech — промышленная биотехнология: разрабатывает, производит и распространяет специальные ферменты, микробные штаммы-продуценты и биорешения для пищевой отрасли, наук о жизни и экологии.

Пока не указана поставщиком в решениях с доказательствами.

Дочерние компании: BRAIN UK II Ltd. · Biocatalysts Ltd. · Biocatalysts Inc. · WeissBioTech GmbH · Breatec B.V. · RMH AG · AnalytiCon Discovery LLC · Biosun Biochemicals Inc.

• 2026-10 Последний статус: С 1 октября 2026 г. председателем правления (CEO) назначен д-р Свен К. Вебер вместо Адриана Мулкера. ↗ ↗ ↗
• 2026-07-29 Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG | Corporate - EQS News
  Dr. Brain Biotech AG will appoint Dr. Sven K. Weber as CEO (effective Oct 1, 2026), with current CEO Adriaan Moelker retiring by Jan 2027 but staying as a senior advisor until then; the company emphasizes continued growth in specialty enzymes, expansion via …
• 2026-07-13 BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH | Ad-hoc - EQS News
  BRAIN Biotech AG has arranged a new €9.0 million revolving credit facility with MP Beteiligungs-GmbH, maturing December 31, 2028, with interest at 6-month Euribor plus 233 basis points, intended for general corporate financing and debt servicing.
• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News
  BRAIN Biotech AG has received an additional EUR 11.51 million milestone payment from Royalty Pharma for progress on the investigational compound deucrictibant, boosting expected future payments up to EUR 96.65 million. The deal also triggers a one-time …
• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News
  BRAIN Biotech AG reports a new EUR 11.51 million milestone payment from Royalty Pharma tied to progress of the investigational drug deucrictibant, boosting expectations for further up to EUR 96.65 million in future milestones. It also notes a one-time non-cash …
• 2026-05-28 BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance | BRAIN Biotech Group
  BRAIN Biotech reports first-half 2025/26 revenue of €23.4m (down 7.2% YoY) with adjusted EBITDA near break-even (-€0.1m) and notes production relocations affecting Biocatalysts sales, while highlighting strong progress in its BRAINBioIncubator with a granted …
• 2026-02-25 BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds | Corporate - EQS News
  BRAIN Biotech AG reports a mixed start to FY 2025/26 with revenue at €11.9m (down 9% YoY) but an improved adjusted EBITDA of €0.3m, driven by the BRAINBioIncubator segment through milestone income from the deucrictibant program. The company highlights …

Владельцы и инвесторы 8

Партнёры и сделки 1

Похожие компании

Biocatalysts Ltd · c-LEcta GmbH · Biocatalysts Baking · Leaf by Lesaffre · Biocatalysts Beverages · BiCT srl - Biological and Chemical Technologies · Bio Base Europe Pilot Plant · Global BioTech S.L